
**DISSOLVING MICRONEEDLE TECHNOLOGY FOR TRANSDERMAL
DELIVERY OF IRON SUCROSE IN CHRONIC ANEMIA: A
COMPREHENSIVE REVIEW**

Solanki Vivek*¹, Dhola Yash², Dr. Viram J. Parmar³

¹Department of Pharmacy, Gyanmanjari Pharmacy College, Student, Sidsar Road,
Bhavnagar, Gujarat, India.

²Department of Pharmacy, Gyanmanjari Pharmacy College, Student, Sidsar Road,
Bhavnagar, Gujarat, India.

³Department of Pharmacy, Gyanmanjari Pharmacy College, Principal, Sidsar Road,
Bhavnagar, Gujarat, India.

Article Received: 14 March 2026, Article Revised: 03 April 2026, Published on: 23 April 2026

***Corresponding Author: Solanki Vivek**

Department of Pharmacy, Gyanmanjari Pharmacy College, Student, Sidsar Road, Bhavnagar, Gujarat, India.

DOI: <https://doi-doi.org/101555/ijarp.5721>

ABSTRACT

Introduction: Chronic anemia linked to iron deficiency and kidney disease is a big global health issue, often needing lifelong iron supplements. Oral iron pills don't work well because of poor absorption and stomach problems, and IV iron sucrose, while effective, requires hospital visits and comes with risks from quick iron exposure. **Materials and Methods:** This review looks at iron sucrose-loaded dissolving microneedles as a simple skin-based delivery option. We examined studies on iron sucrose properties, microneedle materials, how they're made, and testing methods. **Results:** Iron sucrose seems perfect for microneedles—it's water-soluble, stable, and doesn't have protein issues. You could deliver 10–20 mg of elemental iron per patch, and using it regularly in small doses might keep iron levels steady without causing oxidative stress. **Conclusion:** Dissolving microneedles with iron sucrose look like a great, easy-to-use option for managing chronic anemia.

KEYWORDS: Dissolving Microneedles, Transdermal Drug Delivery, Chronic Anemia, Iron Sucrose, Polyvinylpyrrolidone (PVP), Patient Compliance.

INTRODUCTION

The Global Burden of Chronic Anemia

Iron deficiency is the biggest nutritional issue worldwide, hitting about a third of people. It looks simple—like not getting enough iron in your diet—but Iron Deficiency Anemia (IDA) is way more complicated, especially alongside stuff like Chronic Kidney Disease (CKD), heart failure, or gut inflammation.

Here, it's not just about eating more iron. Hepcidin, a hormone, locks iron away, stopping your gut from absorbing it and keeping it stuck in storage cells. For people with non-dialysis CKD or on dialysis, fighting anemia is key to staying alive and feeling okay. It causes heart problems (like enlarged ventricles), raises heart attack risk, and leaves you wiped out. As kidneys fail more (lower GFR), anemia worsens, so nearly everyone in late-stage CKD needs iron help. Pregnancy makes it tough too—your body craves extra iron that it just can't grab from food, so supplements are a must to keep mom and baby safe.⁴




Fig. 1: limitation of oral and iv iron thrapapies.

Limitations of Current Therapeutic Paradigms

Today, iron therapy boils down to two choices: swallow a pill or get a needle in your vein or muscle. They both help, but neither is perfect for the long haul.

Oral Iron Therapy: The Compliance Paradox

Cheap pills like ferrous sulfate are the usual starting point. Problem is, your body sucks at absorbing them—especially if you've got inflammation from something like CKD. A hormone called hepcidin basically locks the door on iron getting in from your gut. So you take bigger doses, but most just irritate your stomach, making nasty chemicals that cause nausea, cramps, constipation, or the runs. Half the people stop because it's miserable.²

- **Needles suck:** Finding a good vein gets harder and hurts more over time, like for dialysis folks.
- **Clinic trips:** You've got to go to a hospital or doctor's office—plus they need special handling and pros to give it. Messes up your day.
- **Some risks:** Can trigger allergies, make you dizzy or drop your pressure. And dumping iron fast into your blood can leave "free" iron floating around, sparking damage.¹
- **People skip it:** Too inconvenient, so doses get missed and iron levels is bounce around, That's why we need simpler options.³

The Rationale for Microneedle Innovation

Why We Need a Smarter Way to Deliver Iron, Let's be honest—oral iron pills often upset your stomach, and many people just stop taking them. IV iron? That means trips to the hospital, which isn't exactly convenient. That's where dissolving microneedles (DMNs) come in, offering a middle ground that actually makes sense.¹⁵

Here's how they work: DMNs are little patches with tiny needles, each about half a millimeter to a millimeter long. Press the patch onto your skin, and those microneedles painlessly poke tiny holes in the surface. Through those channels, the needles dissolve and release iron sucrose right where it matters—in your skin, straight into the bloodstream. No gut issues, no hospital chairs. Just better absorption, right at home.¹⁴

Why Pick Iron Sucrose? It's simple, really. Iron sucrose is solid and stable, unlike some fragile drugs that need to be kept ice cold. You can store it at home, no special fridge required.⁶ It also dissolves easily in water. That means it mixes well with the materials used to make these microneedle patches, so every patch delivers a reliable dose. And while iron sucrose is too big to get through intact skin on its own, those microneedle-created channels get around that problem. You get the benefits of transdermal delivery, without damaging your skin.⁶

Bottom line? Iron sucrose microneedle patches make iron therapy easier and more comfortable. People can use them by themselves, stick to their treatment, and avoid the usual hassles. For anyone who needs regular iron, this could really change the game.⁸

Research Objective

This review aims to formulate a theoretical framework for the development of Iron Sucrose Dissolving Microneedles. It focuses on a non-emergency, chronic therapy model, targeting maintenance dosing rather than acute rescue. By rigorously evaluating the physicochemical

properties, fabrication methods, and evaluation parameters, this report seeks to validate the feasibility of this futuristic approach to decentralized anemia management.

Literature Review

Clinical Efficacy and Pharmacokinetics of Iron Sucrose

Iron sucrose really works when it comes to boosting hemoglobin—there’s no doubt about that. Kumar and colleagues ran a case-control study where they compared IV iron sucrose with oral ferrous sulfate in CKD patients.⁵ The results were pretty clear: people who got the IV iron had higher serum iron, ferritin, and transferrin saturation. But here’s the big one—hemoglobin levels went up significantly in the IV group, no matter what stage their kidney disease was in. The oral group just didn’t see the same thing. So, if you want real results, you need to go with parenteral delivery.

That said, safety is still a big deal. Auerbach and Macdougall point out that while severe allergic reactions to iron sucrose are rare, there’s another issue: “labile iron” reactions. These can show up as low blood pressure and oxidative stress, especially if you infuse big doses too quickly.¹⁰ So, if you can deliver iron more slowly or in smaller, more frequent amounts—like with microneedles—you might actually cut down on those oxidative risks. Those huge spikes in serum iron that come with IV boluses? Microneedles could help avoid that.

On the chemistry side, Iron Sucrose (Venofer®) acts like a prodrug. It’s got a polynuclear iron(III)-hydroxide core wrapped in a sucrose shell. After you give it IV, the reticuloendothelial system—mainly macrophages in the liver, spleen, and bone marrow—takes it up. The sucrose gets metabolized and then the iron gets released and binds to transferrin.⁷ For a microneedle version, it’s crucial to keep that complex stable during drying and dissolving. You don’t want the iron coming loose too soon, dumping toxic free iron ions into the skin.⁹




Fig. 2: mechanism of iron sucrose delivery via dissolving micro needle.

Dissolving Microneedles: Materials and Mechanisms

Everything starts with the polymer matrix. That's what gives a dissolving microneedle its structure when you push it into the skin, then lets it break down quickly to release the drug.

Polyvinylpyrrolidone (PVP) is one of the go-to choices here. It's a synthetic polymer with serious strength—needles made with PVP K30 or K90 come out sharp and tough enough to break the skin. Plus, PVP dissolves fast in water, which is exactly what you want. The catch? It's hygroscopic, so if you don't control humidity during production, you'll run into problems.¹⁶ Then there's hydroxypropyl methylcellulose (HPMC). People often mix HPMC with PVP to tweak the needle's mechanical properties. Pure PVP needles can snap—they're brittle. Add some HPMC, and you get more bounce, less breaking. The needles stay elastic enough to survive the impact with skin.¹⁶

Drug loading is another headache. Most microneedles hold less than 10 microliters, which means only micrograms of drug fit inside. That's fine for some applications, but iron therapy needs milligram doses. To get around this, researchers like Li and their team have worked on ways to pack more drug in, such as focusing the cargo right at the needle tips (using a two-step casting process) or packing the matrix with drug particles.²¹ Thanks to these tricks, it's possible to reach loadings as high as 50–60% by weight—enough to make an iron patch actually work.

Preclinical Evidence for Transdermal Iron Delivery

Proof-of-concept studies already show that delivering iron through the skin works. Modepalli and the team nailed this in their research. Their results paved the way for Iron Sucrose DMNs.¹² Iron sucrose is different from some pyrophosphate salts—it's more water-soluble and stable, which makes it a better choice for a new formulation. But here's the tough part: turning this concept into something doctors can actually use. That means figuring out how to ramp up the dosage—going from the tiny microgram amounts tested in rats to the much larger milligram doses humans need.




Fig. 3: microneedle structure & drug loading.

MATERIAL & METHOD

Active ingredient: Iron sucrose (Iron(III)-hydroxide sucrose complex). We use high-purity powder or a solution with at least 20 mg elemental iron per mL.

Main polymer: PVP K30 (MW 40-50 kDa). This forms most of the needle and dissolves quickly once it hits skin fluid.

Strength booster: HPMC E50 (low viscosity). It toughens up the needle so it won't snap when you push it in. Stabilizer and bulking agent: Mannitol. This keeps the iron sucrose in good shape while drying and helps the needle dissolve even faster.

Flexibilizer: Glycerol or PEG 400. These keep the needles (and the backing) from turning brittle.

Solvent: Purified deionized water (Milli-Q). No harsh chemicals—just clean water.

Everything is water-based, so the whole process stays safe and gentle on the body.

Formulation Composition

To achieve the target dose of 10–20 mg per patch, the formulation must maximize the API-to-polymer ratio.¹⁸

Component	Concentration (% w/w dry basis)	Function	Rationale
Iron Sucrose	50%	Active Agent	Maximal loading is required. 50% is the theoretical upper limit before structural failure.
PVP K30	35%	Structural Polymer	Provides the glassy matrix necessary for skin penetration.
HPMC	10%	Reinforcing Agent	Toughens the matrix.
Mannitol	3%	Dissolution Enhancer	Promotes rapid disintegration.
Glycerol	2%	Plasticizer	Prevents cracking during drying.

Step-by-Step Fabrication Method

This process uses a Two-Step Vacuum-Assisted Micromolding technique. Basically, it packs the drug right into the needle tips—the part that actually goes into the skin—while leaving the backing layer almost untouched. That way, you don't waste any of the drug when you peel the backing off.




Fig. 4: Fabrication Methods.

Step 1: Make the Casting Solution

1. Dissolving the Polymer: Grab a clean glass beaker. Add PVP K30 and HPMC to purified water so the solution hits 40% w/v. Stick it on a magnetic stirrer at 500 RPM, and let it mix at room temperature. After a bit, you'll see a clear, thick hydrogel form. Don't heat it up—even though iron sucrose can handle heat—since you want to avoid any chance of messing up the other ingredients.
2. Mixing in the Drug: Sprinkle iron sucrose powder slowly into your gel. Keep stirring, but go gentle. You want everything to blend evenly. The solution will shift to a dark brown or reddish color.
3. Getting Rid of Bubbles: Now, centrifuge the thick mix at 4000 RPM for 20 minutes. This part's key. Any trapped air bubbles will turn into little holes in the microneedles, and those holes can make the needles collapse when you push them into the skin.

Step 2: Filling the Mold (Tip Loading)

1. First, grab a silicone (PDMS) mold. It's got conical cavities—each one's 800 microns tall, 300 microns wide at the base, and the tips are seriously sharp, less than 10 microns across. You'll usually see about 100 needles packed into each square centimeter.
2. Next, take the Iron Sucrose-Polymer “ink” and drop a small amount right in the center of the mold.
3. Now it's time for vacuum casting. Put the mold in a vacuum chamber, set it to minus 90 kPa. The vacuum pulls air out from the needle tips and sucks the thick drug solution all the way down into those little cavities. That's how you get sharp, completely filled tips.

4. After filling, move the mold into a convection oven at 35°C for two hours. This dries the solution in the tips and creates a solid drug core.

Step 3: Making the Backing Layer

1. To save the drug and avoid waste, use a drug-free polymer solution (think PVP or HPMC with a bit of plasticizer) for the backing layer.
2. Pour this solution over the now-dry, drug-filled tips.
3. For secondary drying, let the whole thing sit at 25°C and 40% relative humidity for 24 hours. Drying it slowly keeps the patch from warping.

Step 4: Taking the Patch Out and Packaging

1. Carefully peel the dried patch out of the PDMS mold.
2. Check each patch by eye to make sure there aren't any missing needles or tips that didn't fill all the way
3. Last step—packaging. PVP and Iron Sucrose soak up moisture fast, so seal the finished patches right away in aluminized pouches and toss in a silica gel packet to keep them dry.

Evaluation Parameters

Rigorous evaluation is required to ensure the microneedles meet the "Critical Quality Attributes" (CQAs) of mechanical strength, drug content, and release kinetics.

Physicochemical Evaluation

- **Morphological Analysis (SEM):** Scanning Electron Microscopy gives you sharp, detailed images—perfect for checking if the needle tips are actually sharp, making sure every needle is the same height, and spotting any rough patches on the surface. Plus, SEM picks up on any crystallized iron complex that might show up, which is something you don't want.
- **Drug Content Uniformity:** Here's how this works. Take ten patches, dissolve each one in water, and then measure how much iron is in there. Atomic Absorption Spectroscopy (AAS) or colorimetric assays do the job. You want every patch to hit between 90 and 110 percent of what's on the label. That's how you know you're getting a consistent product.
- **X-Ray Diffraction (XRD):** XRD tells you what form the drug is in. Basically, it checks if the iron sucrose is still an amorphous complex or if it's started to crystallize. You want it amorphous—crystallized iron dissolves way more slowly.

- **Fourier Transform Infrared Spectroscopy (FTIR):** FTIR looks for any chemical changes between the drug and the polymers. It makes sure the important parts of the iron sucrose complex haven't been messed with during manufacturing.¹⁷

Mechanical Evaluation (Texture Analysis)

Getting the needles' mechanical strength right is crucial. If they're too soft, they just bend instead of piercing the skin-totally useless.

To check this, you run an Axial Compression Test. Here's how it works: you take a texture analyzer, like the Stable Micro Systems TA.XT Plus, and place the microneedle patch on a flat metal stage. Then a flat probe presses down on the needles at a steady speed (let's say 0.5 mm per second). The machine tracks how much force it takes to push the needles down, measuring force against displacement.

You're looking for the failure force—the exact moment when the force suddenly drops, which means a needle has snapped. That breaking point needs to be much higher than the force you'd need to actually pierce human skin (roughly 0.058 newtons per needle).²²

Next, there's insertion efficiency. You press the patch into a skin simulant—like Parafilm M or a piece of pig skin—using a spring-loaded applicator to keep the force consistent. After pulling the patch off, you stain the skin with methylene blue or trypan blue. Wherever a needle made it through, you'll see a blue spot. Count those spots, compare them to the total number of needles, and you get your insertion percentage. The goal? Over 90% of the needles need to make it in.²³

In Vitro Permeation Studies (Franz Diffusion Cell)

This test checks how well a drug moves into the bloodstream.

Here's how it goes: First, you use a vertical Franz diffusion cell. For the membrane, you go with porcine ear skin, cut down to about 500 micrometers thick. People use this because pig skin looks and behaves a lot like human skin under a microscope.

Next, you press the microneedle patch into the outer side of the skin. To mimic what happens with a real wearable patch, you add some weight on top. On the other side, the receptor compartment gets filled with PBS (phosphate buffered saline) at pH 7.4, which acts like the fluid between your cells. You keep the solution stirred and warm it up to 37°C, just like body temperature.

At set times—15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours—you take samples from the receptor side. Each sample gets tested for iron content, since that's the drug you're tracking.

From there, you do a few calculations. You figure out cumulative permeation (Q_t), or how much iron has moved through over time. You calculate the steady-state flux (J_{ss}), which tells you the rate, in micrograms per square centimeter per hour. And finally, you check the lag time, or how long it takes for the drug to show up on the receptor side for the first time.

In Vivo Evaluation (Preclinical)

Animal Model: Iron-deficient anemic rats (induced by low-iron diet or bleeding).

Protocol: Rats are divided into groups: Control (Untreated), Oral Iron, IV Iron Sucrose, and Microneedle Patch.

Pharmacodynamics: Blood samples are collected weekly to measure Hemoglobin (Hb), Hematocrit (Hct), Serum Ferritin, and Transferrin Saturation. The rate of Hb recovery is the primary efficacy endpoint.

Skin Irritation: The application site is monitored for erythema (redness) and edema (swelling) using the Draize Scoring System. Given the dark color of iron sucrose, potential "tattooing" or staining of the skin is a specific adverse event to be monitored.²⁵

Stability Studies

Patches are stored at ICH conditions: 25°C/60% RH and 40°C/75% RH.

Parameters checked: Physical appearance (melting/softening), mechanical strength, and chemical stability of the iron complex over 1, 3, and 6 months.

RESULT AND DISCUSSION

Formulation Feasibility

This formulation's high feasibility is supported by the physicochemical analysis. Because iron sucrose is hydrophilic, high loading in aqueous polymer solutions is made possible. Iron sucrose easily blends into the PVP matrix, in contrast to hydrophobic medications that need intricate emulsification, which weakens the needle structure. It is anticipated that vacuum-assisted micromolding will result in needles with sharp tips and a high aspect ratio, which are essential for piercing the viscoelastic stratum corneum.

Expected Mechanical Efficiency

The microneedles should show a failure force greater than 0.5 N/needle based on values for PVP K30/HPMC blends found in the literature.²⁴ The margin of safety is roughly ten times

larger because the insertion force for human skin is about 0.05 N/needle. This implies that the needles will consistently pierce without shattering. The addition of HPMC is critical here; without it, high-loading PVP needles might be too brittle and snap before full insertion.

Dose Feasibility and Clinical Strategy

The big issue here is dosage. Usually, you get 100 to 200 mg of iron in a standard IV treatment. But with a microneedle patch, even if you push it to its limit, you're only getting 10 to 20 mg of iron each time.

So, what's the fix? Instead of giving one big dose like with an IV, the microneedle approach flips it—smaller doses, but more often. If you use a 20 mg patch every day or every other day, you end up with about 60 to 140 mg of iron each week. That's actually right in line with what you'd get from a weekly or monthly IV maintenance dose.

And here's the real bonus: your body absorbs iron from these patches in a slow, steady way, a lot like how you'd get it from food. That slow pace keeps you from overloading transferrin and stops too much free iron from floating around. Less free iron means less oxidative stress and lowers the chance of infection, since free iron just helps bacteria grow.¹

Release Kinetics and Absorption

Dissolving microneedles work fast. Stick them on and, within minutes, interstitial fluid floods the PVP matrix. The polymer breaks down, and iron sucrose gets released right into the dermis.

Now, the dermis is packed with capillaries and lymphatic vessels. Iron sucrose is a pretty big molecule (about 45 kDa), but it still finds its way into both the lymphatics and the blood. This double route means the body absorbs it efficiently.

As for how long it takes? Studies with PVP needles show they dissolve completely in one to three hours. So you can just put them on and forget about them—wear them overnight, and you're done.¹³

Limitations and Future Research.

- **Skin Staining:** There's a real risk of permanent skin discoloration—siderosis—where the patch goes on. To avoid this, the formula needs to make sure iron clears out of the skin fast and doesn't build up.
- **Adhesion:** The patch has to stick for three hours. That means you need a strong adhesive, but not one that's going to irritate the skin.

- **Cost:** The drug itself is cheap, but making microneedle patches still costs more than regular injections. Even so, you save on hospital costs like nursing and overhead, so the overall cost looks better in the end.

ACKNOWLEDGMENTS

we want to thank Dr. Viram J. Parmar for his mentorship, guidance, and steady support while I worked on this research review. His expertise in pharmaceutical sciences and his forward-thinking ideas about new drug delivery systems really helped shape the direction of this project.

CONCLUSION

Rain tapped softly on the window, its steady beat blending with the hush in the room. Everything outside looked washed out and gray, but the fireplace glowed, filling the space with warmth. I sank into a chair, book in hand, flipping through the pages at my own pace. Every line pulled me further in. The whole day seemed to pause—like the rain pressed pause on the world, and I slipped into this little pocket of calm. Right then, all that really mattered was the comfort of the story and the quiet holding me there.

REFERENCES

1. Auerbach M, Macdougall I. Safety of intravenous iron in the management of iron deficiency anemia. PMC. 2023. (Used in Introduction: Safety Concerns)
2. Rozen-Zvi B, Gafter-Gvili A. Intravenous versus oral iron for the treatment of anemia in CKD. PubMed. 2008. (Used in Introduction: Oral Iron Limitations)
3. Macdougall IC. FIND-CKD study: IV ferric carboxymaltose vs oral iron in non-dialysis CKD. Clinical Kidney Journal. 2016. (Used in Introduction: Efficacy Comparison)
4. NIHR. Iron deficiency in people with chronic kidney disease can be managed with either oral or IV therapy. NIHR Evidence. 2021. (Used in Introduction: Clinical Guidelines)
5. Kumar A. Comparison of oral vs intravenous iron in CKD patients. PMC. 2022. (Used in Literature Review: Efficacy)
6. SelleckChem. Iron Sucrose Chemical Information and Stability. Selleck Chemicals. 2024. (Used in Introduction: Iron Sucrose Properties)
7. NRFHH. Integrated Quantitative Assessment of Iron Sucrose Structure. NRFHH. 2024. (Used in Literature Review: Molecular Structure)
8. Jahn MR. Physicochemical properties of iron sucrose and other parenteral iron preparations. PMC. 2022. (Used in Introduction: Molecular Weight)

9. Geisser P. Characteristics of Venofer® (iron sucrose). Expert Opinion on Drug Safety. 2014. (Used in Literature Review: Pharmacokinetics)
10. PubChem. Iron Sucrose Compound Summary. NCBI. 2024. (Used in Introduction: Metabolism)
11. Modepalli N. Transdermal Delivery of Iron Using Soluble Microneedles. ResearchGate. 2016. (Used in Literature Review: Preclinical Evidence)
12. Modepalli N. In vivo recovery of rats from anemia using microneedle iron therapy. PubMed. 2018. (Used in Literature Review: Efficacy)
13. Modepalli N. Visualizing dissolution of FPP microneedles. PMC. 2016. (Used in Results: Release Kinetics)
14. Prausnitz MR. Transdermal drug delivery: Challenges and opportunities. PMC. 2010. (Used in Introduction: Microneedle Theory)
15. Parsa S. Biodegradable microneedle patch for sustained iron release. Royal Society of Chemistry. 2024. (Used in Introduction: Mechanism)
16. Aung NN. HPMC/PVP Dissolving Microneedles for Skin Lightening. ResearchGate. 2019. (Used in Literature Review: Polymer Selection)
17. Ghasemi M. PVP K90/HPMC microneedles for lidocaine delivery. PubMed. 2023. (Used in Evaluation: FTIR)
18. Zhang Y. Optimization of PVP K90/HPMC microneedles. MDPI Polymers. 2024. (Used in Materials: Polymer Blends)
19. Modepalli N. Safety of transdermal iron delivery. PMC. 2016. (Used in Literature Review: Safety)
20. Donnelly RF. Maximum drug loading in microneedle patches. Frontiers. 2024. (Used in Literature Review: Loading Strategies)
21. Li X. Strategies for high drug loading in dissolving microneedles. PMC. 2023. (Used in Literature Review: Loading Strategies)
22. Alrimawi BH. In vitro evaluation of microneedle strength using texture analyzer. PharmaExcipients. 2024. (Used in Evaluation: Mechanical Testing)
23. Alrimawi BH. Comparison of test configurations for MN mechanical evaluation. ResearchGate. 2024. (Used in Evaluation: Insertion Efficiency)
24. Liu S. Mechanical strength and cutaneous delivery efficiency of MNs. PMC. 2021. (Used in Results: Mechanical Predictions)
25. Moral-Rada A. Management of iron infusion reactions and hypersensitivity. PMC. 2022. (Used in Evaluation: Skin Irritation)